The US Food and Drug Administration’s Oncology Center of Excellence is planning to make reviews of “dangling” or “delinquent” accelerated approvals a routine agenda topic for the Oncologic Drugs Advisory Committee to build on the momentum toward assuring timely confirmatory study results that it established in 2021.
“This is my Jihad,” OCE Director Richard Pazdur said during a Zoom panel discussion as part of the Prevision Policy/Friends of Cancer Research Biopharma Congress. “It isn’t a momentary, one-year event. It will continue
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?